Citation: | XU Mei-ling, XING Bao-tong, LI Jian-ping. Study on the Combination of Salviae Miltiorrhizae Radix et Rhizoma and Carthami Flos to Regulate Unfolded Protein Response and Improve Cardiac Function in Mice with Diabetic Cardiomyopathy[J]. Journal of Nanjing University of traditional Chinese Medicine, 2023, 39(9): 910-917. doi: 10.14148/j.issn.1672-0482.2023.0910 |
[1] |
KIM AH, JANG JE, HAN J. Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy[J]. Biomed Pharmacother, 2022, 145: 112463. doi: 10.1016/j.biopha.2021.112463
|
[2] |
DANAEI G, LAWES CMM, VANDER HOORN S, et al. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: Comparative risk assessment[J]. Lancet, 2006, 368(9548): 1651-1659. doi: 10.1016/S0140-6736(06)69700-6
|
[3] |
COLLABORATION ERF, SARWAR N, GAO P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies[J]. Lancet, 2010, 375(9733): 2215-2222. doi: 10.1016/S0140-6736(10)60484-9
|
[4] |
SEFEROVIĆ PM, PAULUS WJ. Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes[J]. Eur Heart J, 2015, 36(27): 1718-1727, 1727a-1727c. doi: 10.1093/eurheartj/ehv134
|
[5] |
BATTIPROLU PK, LOPEZ-CRISOSTO C, WANG ZV, et al. Diabetic cardiomyopathy and metabolic remodeling of the heart[J]. Life Sci, 2013, 92(11): 609-615. doi: 10.1016/j.lfs.2012.10.011
|
[6] |
JIA GH, DEMARCO VG, SOWERS JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy[J]. Nat Rev Endocrinol, 2016, 12(3): 144-153. doi: 10.1038/nrendo.2015.216
|
[7] |
JIA GH, WHALEY-CONNELL A, SOWERS JR. Diabetic cardiomyopathy: A hyperglycaemia- and insulin-resistance-induced heart disease[J]. Diabetologia, 2018, 61(1): 21-28. doi: 10.1007/s00125-017-4390-4
|
[8] |
TAN Y, ZHANG ZG, ZHENG C, et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: Preclinical and clinical evidence[J]. Nat Rev Cardiol, 2020, 17(9): 585-607. doi: 10.1038/s41569-020-0339-2
|
[9] |
GIUGLIANO D, MEIER JJ, ESPOSITO K. Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope[J]. Diabetes Obes Metab, 2019, 21(5): 1081-1087. doi: 10.1111/dom.13629
|
[10] |
QUAN C, DU Q, LI M, et al. A PKB-SPEG signaling nexus links insulin resistance with diabetic cardiomyopathy by regulating calcium homeostasis[J]. Nat Commun, 2020, 11(1): 2186. doi: 10.1038/s41467-020-16116-9
|
[11] |
ORGAH JO, HE S, WANG YL, et al. Pharmacological potential of the combination of Salvia miltiorrhiza (Danshen) and Carthamus tinctorius (Honghua) for diabetes mellitus and its cardiovascular complications[J]. Pharmacol Res, 2020, 153: 104654. doi: 10.1016/j.phrs.2020.104654
|
[12] |
李建萍, 徐雪君, 张沁瑜, 等. 丹参-红花配伍调控胰岛素信号通路改善小鼠胰岛素抵抗的作用机制研究[J]. 药学学报, 2021, 56(4): 1049-1056.
LI JP, XU XJ, ZHANG QY, et al. Compatibility of Salviae Miltiorrhizae Radix et Rhizoma and Carthami Flos regulate insulin signaling pathway and alleviate insulin resistance in mice[J]. Acta Pharm Sin, 2021, 56(4): 1049-1056.
|
[13] |
LI JP, XU ML, XING BT, et al. Combination of Salviae Miltiorrhizae Radix et Rhizoma and Carthami Flos improves cardiac function of diabetic cardiomyopathy mice by regulating the unfolded protein response signaling pathway[J]. Phytother Res, 2022, 36(9): 3571-3583. doi: 10.1002/ptr.7524
|
[14] |
HEINRICH M, APPENDINO G, EFFERTH T, et al. Best practice in research-Overcoming common challenges in phytopharmacological research[J]. J Ethnopharmacol, 2020, 246: 112230. doi: 10.1016/j.jep.2019.112230
|
[15] |
IZZO AA, TEIXEIRA M, ALEXANDER SPH, et al. A practical guide for transparent reporting of research on natural products in the British Journal of Pharmacology: Reproducibility of natural product research[J]. Br J Pharmacol, 2020, 177(10): 2169-2178. doi: 10.1111/bph.15054
|
[16] |
NAGY C, EINWALLNER E. Study of in vivo glucose metabolism in high-fat diet-fed mice using oral glucose tolerance test (OGTT) and insulin tolerance test (ITT)[J]. J Vis Exp, 2018(131): 56672.
|
[17] |
WANG ZV, DENG YF, GAO NG, et al. Spliced X-box binding protein 1 couples the unfolded protein response to hexosamine biosynthetic pathway[J]. Cell, 2014, 156(6): 1179-1192. doi: 10.1016/j.cell.2014.01.014
|
[18] |
AHMAD I, HODA M. Molecular mechanisms of action of resveratrol in modulation of diabetic and non-diabetic cardiomyopathy[J]. Pharmacol Res, 2020, 161: 105112. doi: 10.1016/j.phrs.2020.105112
|
[19] |
SHARMA AK, SRINIVASAN BP. Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats[J]. Eur J Pharm Sci, 2009, 38(5): 433-444. doi: 10.1016/j.ejps.2009.09.004
|
[20] |
GREMPLER R, THOMAS L, ECKHARDT M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors[J]. Diabetes Obes Metab, 2012, 14(1): 83-90. doi: 10.1111/j.1463-1326.2011.01517.x
|
[21] |
HOLMAN RR, PAUL SK, BETHEL MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes[J]. N Engl J Med, 2008, 359(15): 1577-1589. doi: 10.1056/NEJMoa0806470
|
[22] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 国际内分泌代谢杂志, 2021, 41(5): 482-548. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYX202112018.htm
Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)[J]. Int J Endocrinol Metab, 2021, 41(5): 482-548. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYX202112018.htm
|
[23] |
PAN GD, DESHPANDE M, PANG HY, et al. Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2*2 mutation, a specific genetic mutation in millions of East Asians[J]. Eur J Pharmacol, 2018, 839: 76-81. doi: 10.1016/j.ejphar.2018.09.021
|
[24] |
WANG M, KAUFMAN RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development[J]. Nat Rev Cancer, 2014, 14(9): 581-597. doi: 10.1038/nrc3800
|
[25] |
SZEGEZDI E, LOGUE SE, GORMAN AM, et al. Mediators of endoplasmic reticulum stress-induced apoptosis[J]. EMBO Rep, 2006, 7(9): 880-885. doi: 10.1038/sj.embor.7400779
|